| Study characteristics |
| Methods |
Prospective, controlled study |
| Participants |
Individuals under age 65 who had experienced at least 1 transient atherothrombotic cerebral event according to Joint Committee for Stroke facilities |
| Interventions |
Dipyridamole 400 mg per day vs aspirin 100 mg + dipyridamole 300 mg per day |
| Outcomes |
Ischaemic events (stroke, TIA), deaths (stroke, cardiovascular, all‐cause mortality) |
| Notes |
Subanalysis of participants recruited early in a secondary prevention trial |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Random sequence generation (selection bias) |
Unclear risk |
No information regarding randomisation |
| Allocation concealment (selection bias) |
Unclear risk |
No method described |
| Blinding of participants and personnel (performance bias)
All outcomes |
Unclear risk |
No description of placebo pills provided |
| Blinding of outcome assessment (detection bias)
All outcomes |
Unclear risk |
No method described |
| Incomplete outcome data (attrition bias)
All outcomes |
Low risk |
11 of 197 (5.6%) participants enrolled lost to follow‐up |
| Selective reporting (reporting bias) |
Low risk |
Outcomes reported |
